Arcadia Medicine

A new generation
of cognitive medicine

Arcadia Medicine is engineering safe and effective mental health therapies

Arcadia was created to bring safe empathogens to patients and transform the mental health therapeutics space

Our mission is to scale safe and effective drug-assisted mental health therapies to reach patients in need across the globe

A better version of
MDMA

Our lead candidate is AM-1002

AM-1002 is in early development, the performance of AM-1002 has not be established nor has AM-1002 been approved by the FDA for any indication

Engineered to be safe with limited side effects

Developed to be non-neurotoxic, reduce hyperthermia, and have few cardiovascular side effects

Flexible dosing

Designed to accommodate a range of safe doses potentially allowing for more precise therapy and ongoing treatment options

Engineered for optimal effect

Designed to selectively release serotonin and oxytocin which is expected to drive therapeutic effect

Our Pipeline

Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed

Drug

Candidate properties

Status

AM-1002
(PTSD)
Post-Traumatic Stress Disorder

Designed to be a non-racemic, non-neurotoxic form of MDMA with an improved therapeutic profile

Development

Preclinical

Phase I/II

Phase III

AM-1004
(MDD)
Major Depressive
Disorder

Designed to be a short-acting psychoactive-empathogen combination therapy with an improved therapeutic profile

Development

Preclinical

Phase I/II

Phase III

AM-1006
(SUD)
Substance Use
Disorder

A subperceptual psychoactive drug designed to produce a short acting effect for use in a traditional hour-long therapeutic setting

Development

Preclinical

Phase I/II

Phase III

Our Pipeline

Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed with existing psychedelic medicine

Drug

AM-1002 (PTSD)
Post-Traumatic Stress Disorder

Indication

A non-racemic, non-neurotoxic form of MDMA with an improved therapeutic profile.

Status

Development

Preclinical

Phase I/II

Phase III

Drug

AM-1004 (MDD)
Major Depressive Disorder

Indication

A short-acting psychoactive-empathogen combination therapy with an improved therapeutic profile

Status

Development

Preclinical

Phase I/II

Phase III

Drug

AM-1006 (SA)
Substance Abuse 

Indication

A non-racemic, non-neurotoxic form of MDMA with an improved therapeutic profile.

Status

Development

Preclinical

Phase I/II

Phase III

Arcadia’s pharmacological model identifies optimal drug pharmacology profiles based on relevant receptor affinity, enantioselective metabolic profile, and existing safety and tolerance data.

Top candidates and combinations are evaluated based on their pharmacology, pharmacokinetics, and half-life to optimize expected safety and efficacy.

Our model generates extensive datasets, which are used to continuously curate and refine the prediction process, both before and during preclinical evaluation.

Next Gen
Discovery
Platform

Predict

Select

Learn

Investors